Pfizer has signed a license agreement with TransTech Pharma Inc worth at least $155 million for the development and commercialisation of Receptor for Advanced Glycation End-products (RAGE) modulators which could potentially be used in Alzheimer's Disease.
Pfizer will pay privately-held TransTech upfront and near-term milestone payments, with the potential for significant additional milestone payments, and gains the exclusive world-wide rights to develop and sell TransTech's range of RAGE modulators.
No comments:
Post a Comment